Novartis wants to appeal a ruling in its dispute with generic drug maker Pharmacor over patents for its multiple sclerosis drug Gilenya that tossed three of its four experts out of an upcoming so-called hot tub.
A judge has slammed Novartis for putting forward four “overlapping” experts in a dispute with Pharmacor over patents for its MS drug Gilenya and thrown three of those experts out of an upcoming joint conferral, known as a “hot tub”.
Concrete repair company Vector Corrosion Technologies has lost its bid for ownership of a concrete treatment patent held by three former employees who jumped ship, with a court finding the trio invented the technology after leaving Vector.
Seven Network is in negotiations with Bangkok Broadcasting to resolve their spat over the Thai broadcaster’s proposed 7HD trade mark, which was found to be deceptively similar to Seven’s mark.
A judge has found Pfizer’s patent for its post-operative injectable painkiller Dynastat is valid and that Australian drug maker Juno Pharmaceuticals infringed the patent by selling generic versions of the drug in Australia.
Five years into a preliminary discovery application for a potential patent infringement lawsuit over a biosimilar of its Enbrel medication, Pfizer has partially succeeded in obtaining further documents from Samsung Bioepis.
An Australian generic drug manufacturer has struck back at patent lawsuit by Swiss pharmaceutical company Biogen, alleging a patent for MS drug Tecfidera is invalid and a that a patent term extension for the drug was wrongly granted.
US-based chemical and materials technology company Cytec Industries has won its Federal Court challenge to a mining patent application by a unit of Ecolab, with the court finding the claims in the patent lacked support and sufficient disclosure.
Coffee capsule machine manufacturer Caffitaly has saved one of its coffee pod patents from a finding of invalidity, in a partially successful appeal of a ruling that stripped three of its patents from the Australian register.
Juno Pharmaceuticals has backed away from its plans to launch a generic version of HIV drug Prezista in Australia after being hit with a patent lawsuit by Janssen, becoming the second generic drug maker to capitulate to the Johnson & Johnson-owned company’s demands.